University of North Carolina, Chapel Hill, NC, USA.
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1385-9. doi: 10.1002/acr.21964.
Palpable tendon friction rubs (TFRs) in systemic sclerosis (SSc; scleroderma) have been associated with diffuse skin thickening, increased disability, and poor survival. Our objective was to quantify the prognostic implications of palpable TFRs on the development of disease complications and longer-term mortality in an incident cohort of early diffuse cutaneous SSc (dcSSc) patients.
We identified early dcSSc patients (disease duration <2 years from the first SSc symptom) first evaluated at the University of Pittsburgh Scleroderma Center between 1980 and 2006 and found to have palpable TFRs. These patients were matched 1:1 with the next consecutive early dcSSc patient without TFRs as a control. All had ≥2 clinic visits and 5 years of followup from the first visit.
A total of 287 early dcSSc patients with TFR were identified and matched to 287 controls. The median disease duration was 0.83 years in TFR patients and 1.04 years in controls. The median followup was 10.1 years in TFR patients and 7.9 years in controls. Over the course of their illness, patients with TFRs had a >2-fold risk of developing renal crisis and cardiac and gastrointestinal disease complications, even after adjustment for other known risk factors. Patients with TFRs had poorer 5- and 10-year survival rates.
Patients with early dcSSc having ≥1 TFRs are at an increased risk of developing renal, cardiac, and gastrointestinal involvement before and after their first Scleroderma Center visit and have reduced survival. Patients presenting with TFRs should be carefully monitored for serious internal organ involvement.
系统性硬化症(SSc;硬皮病)中可触及的肌腱摩擦音(TFRs)与弥漫性皮肤增厚、残疾程度增加和生存不良有关。我们的目的是在早期弥漫性皮肤型 SSc(dcSSc)患者的队列中,量化可触及 TFRs 对疾病并发症发展和长期死亡率的预后意义。
我们确定了 1980 年至 2006 年期间在匹兹堡 Scleroderma 中心首次接受评估的早期 dcSSc 患者(从第一个 SSc 症状开始的疾病持续时间<2 年),并发现了可触及的 TFRs。这些患者与下一个连续的早期无 TFR 的 dcSSc 患者进行了 1:1 匹配作为对照。所有患者均有≥2 次就诊和从首次就诊开始的 5 年随访。
共确定了 287 例有 TFR 的早期 dcSSc 患者,并与 287 名对照相匹配。TFR 患者的中位疾病持续时间为 0.83 年,对照组为 1.04 年。TFR 患者的中位随访时间为 10.1 年,对照组为 7.9 年。在他们的疾病过程中,即使在调整了其他已知的危险因素后,TFR 患者发生肾危象以及心脏和胃肠道疾病并发症的风险也增加了两倍以上。TFR 患者的 5 年和 10 年生存率较低。
早期 dcSSc 患者有≥1 个 TFR 时,在首次就诊前后发生肾、心脏和胃肠道受累的风险增加,生存率降低。出现 TFR 的患者应密切监测严重的内脏器官受累情况。